Worldwide Repeat Expansion Disorders Treatment Industry to 2030 - North America Remains as the Global Leader and APAC to Present the Largest Opportunity - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Repeat Expansion Disorders Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.

The market for repeat expansion disorders treatment is expected to grow at a CAGR of 13.5% during the forecast period of 2022 to 2030.

Companies Mentioned

• Pfizer Inc.
• CRISPR Therapeutics
• Acorda Therapeutics
• Capsida Biotherapeutics Inc.
• Larimar Therapeutics Inc.
• Healx
• Intellia Therapeutics Inc.
• Editas Medicine
• Bluebird bio Inc.
• Sanofi
• Merck & Co. Inc.
• H. Lundbeck A/S
• Cellectis SA
• Bio-Techne
• GlaxoSmithKline plc
• Allergan Aurobindo Pharma Ltd.
• Sun Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Intas Pharmaceuticals Ltd.
• Cipla Ltd

Repeat expansion disorders are a group of inherited conditions that are triggered by expansions in the DNA repeats of affected individuals. The length of the DNA repeats can range from a single nucleotide all the way up to a dodecamer or even longer. The point at which the repetitive expansions start to cause symptoms differs from one disease to another depending on what it is. These expansions in DNA sequence are now known to be the root cause of over 40 different illnesses.

The causal mutations that drive pathogenesis in a substantial number of these disorders have been recognised thanks to remarkable progress that has been made over the past three decades. The expansion of CAG, GCG, CTG, CGG, and CAAA repeats both in coding and non-coding regions in separate genes results in a wide set of disorders with processes associated to protein levels or toxicity, RNA, and/or both. These repeats can be found in either coding or non-coding sequences.

Increasing Research of Rapid Expansion Disorders Therapies is Boosting the Market

Because of the complexity of repetitive disease genetics and pathobiology, previously unknown commonalities and molecular mechanisms associated with the diseases, such as RNA toxicity, have been uncovered. The investigation of polyglutamine diseases has also shown that post-translational modification is an important step in the pathogenic cascade, and it has demonstrated that the autophagy pathway plays an important role in the degradation of misfolded proteins.

Market to Present Significant Opportunities During the Forecast Period

Since the first discovery of a novel and obscure type of mutation as the root cause of fragile X syndrome and spinal muscular atrophy (SBMA), a significant amount of progress has been made. The research that has been done in this area has uncovered an extraordinary unanticipated complexity, which includes toxicities that are mediated at the protein, RNA, and genome levels.

North America Remains as the Global Leader and APAC to Present the Largest Opportunity

In 2021, North America held the dominant position in the market for treatments for Huntington's disease, holding a revenue share of 60%. This expansion is due to the high burden of the disease, increased healthcare expenditure, technological advancements, proactive government initiatives, and increased patient awareness about treatments available for rapid expansion disorders treatment. Specifically, the high burden of the disease is causing increased healthcare expenditure.

Market Segmentation

Disorders

• Dentatorubral-pallido-luysian atrophy (DRPLA)
• Fragile X syndrome ofmental retardation
• Fragile X tremor ataxia syndrome (FXTAS)
• FRAXE mental retardation (FMR2)
• Spinal and Bulbar Muscular Atrophy/Kennedy's Disease
• type1 (SCA1)
• type 2 (SCA2)
• type 3 (SCA3)
• type 6 (SCA6)
• type 7 (SCA7)
• type 8 (SCA8)
• type 10 (SCA10)
• type 12 (SCA12)
• type 17 (SCA17)
• Huntington's Disease
• Oculopharyngeal musculardystrophy (OPMD)
• Myoclonic epilepsy type 1
• Myotonic dystrophy
• Type 1
• Type 2
• Spinocerebellar ataxia
• Friedreich Ataxia
• Amyotrophic lateral sclerosis (ALS)
• Frontotemporal dementia (FTD).
• Myoclonic epilepsy
• Syndromic / non-syndromicX-linked mental retardation(Gene: ARX)
• Others

Route of Administration

• Oral
• Injectable

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Drug Pipeline (Profile)

• Spinal and Bulbar Muscular Atrophy/Kennedy's Disease
• Huntington's Disease
• spinocerebellar ataxia
• Friedreich Ataxia
• amyotrophic lateral sclerosis (ALS)
• frontotemporal dementia (FTD)

Region Segment (2020 - 2030; US$ Million)

• North America
• UK and European Union
• Asia Pacific
• Latin America
• Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

• Pre Covid-19 situation
• Post Covid-19 situation

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Repeat Expansion Disorders Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2030.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Repeat Expansion Disorders Treatment market?
• Which is the largest regional market for Repeat Expansion Disorders Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Repeat Expansion Disorders Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Repeat Expansion Disorders Treatment market worldwide?

For more information about this report visit https://www.researchandmarkets.com/r/d1m192